{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(1)"],"submitter":["Naganawa M"],"funding":["UCB Pharma"],"pubmed_abstract":["<h4>Background</h4>Antiepileptic drugs, levetiracetam (LEV) and brivaracetam (BRV), bind to synaptic vesicle glycoprotein 2A (SV2A). In their anti-seizure activity, speed of brain entry may be an important factor. BRV showed faster entry into the human and non-human primate brain, based on more rapid displacement of SV2A tracer <sup>11</sup>C-UCB-J. To extract additional information from previous human studies, we developed a nonlinear model that accounted for drug entry into the brain and binding to SV2A using brain <sup>11</sup>C-UCB-J positron emission tomography (PET) data and the time-varying plasma drug concentration, to assess the kinetic parameter K<sub>1</sub> (brain entry rate) of the drugs.<h4>Method</h4>Displacement (LEV or BRV p.i. 60 min post-tracer injection) and post-dose s"],"journal":["EJNMMI research"],"pagination":["71"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9643320"],"repository":["biostudies-literature"],"pubmed_title":["Drug characteristics derived from kinetic modeling: combined <sup>11</sup>C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2A."],"pmcid":["PMC9643320"],"pubmed_authors":["Hannestad J","Kervyn S","Chen MK","Mercier J","Naganawa M","Stockis A","Nabulsi NB","Gallezot JD","Huang Y","Henry S","Carson RE","Finnema SJ","Maguire RP","Nicolas JM","Klitgaard H"],"additional_accession":[]},"is_claimable":false,"name":"Drug characteristics derived from kinetic modeling: combined <sup>11</sup>C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2A.","description":"<h4>Background</h4>Antiepileptic drugs, levetiracetam (LEV) and brivaracetam (BRV), bind to synaptic vesicle glycoprotein 2A (SV2A). In their anti-seizure activity, speed of brain entry may be an important factor. BRV showed faster entry into the human and non-human primate brain, based on more rapid displacement of SV2A tracer <sup>11</sup>C-UCB-J. To extract additional information from previous human studies, we developed a nonlinear model that accounted for drug entry into the brain and binding to SV2A using brain <sup>11</sup>C-UCB-J positron emission tomography (PET) data and the time-varying plasma drug concentration, to assess the kinetic parameter K<sub>1</sub> (brain entry rate) of the drugs.<h4>Method</h4>Displacement (LEV or BRV p.i. 60 min post-tracer injection) and post-dose s","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-04T19:27:46.036Z","creation":"2025-02-19T01:57:15.144Z"},"accession":"S-EPMC9643320","cross_references":{"pubmed":["36346513"],"doi":["10.1186/s13550-022-00944-5"]}}